Stuart Tross - Amgen Senior Vice President - Human Resources

AMGN Stock  MXN 4,450  6.50  0.15%   

President

Dr. Stuart A. Tross is the Senior Vice President Human Resources of Amgen Inc since 2013.
Age 48
Tenure 11 years
Phone805 447 1000
Webhttps://www.amgen.com
Tross joined the Company in April 2006 as Vice President, Human Resources. Prior to joining Amgen, from November 1998 to April 2006, Dr. Tross served in a series of roles for BMS, with his last position being Vice President and Global Head of Human Resources of Mead Johnson Nutrition. Prior to joining BMS, Dr. Tross was a management consultant for Towers Perrin.

Stuart Tross Latest Insider Activity

Tracking and analyzing the buying and selling activities of Stuart Tross against Amgen stock is an integral part of due diligence when investing in Amgen. Stuart Tross insider activity provides valuable insight into whether Amgen is net buyers or sellers over its current business cycle. Note, Amgen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amgen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Amgen Management Efficiency

The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 37.35 B in total debt with debt to equity ratio (D/E) of 309.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has a current ratio of 2.71, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Andrew IaboniMcEwen Mining
41
Brady ConnorVerizon Communications
N/A
Daniel MeadVerizon Communications
60
Christopher NewkirkCapital One Financial
47
Christopher StewartMcEwen Mining
47
Michael HarringtonFirst Republic Bank
N/A
Anthony SkiadasVerizon Communications
48
Hans VestbergVerizon Communications
58
Jason BenderFirst Republic Bank
47
Anne LloydMartin Marietta Materials
53
Ryan SchneiderCapital One Financial
45
Michael WassmerCapital One Financial
53
Roy ChestnuttVerizon Communications
53
Olga TsokovaFirst Republic Bank
50
Colin SutherlandMcEwen Mining
42
Richard TeetsSteel Dynamics
68
Matthew EllisVerizon Communications
52
John MohrMartin Marietta Materials
58
Simon QuickMcEwen Mining
28
Stephanie BontempsFirst Republic Bank
57
Dale SmithFirst Republic Bank
N/A
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. AMGEN INC operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 21500 people. Amgen Inc (AMGN) is traded on Mexican Exchange in Mexico and employs 25,200 people.

Management Performance

Amgen Inc Leadership Team

Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, VP Officer
Frank Herringer, Independent Director
Nancy Grygiel, Sr Officer
Francois Carbonnel, Independent Director
Rebecca Henderson, Independent Director
Annette Such, Chief Accounting Officer
Sanders Williams, Independent Director
Vance Coffman, Lead Independent Director
David Reese, Executive Vice President - Research and Development
Tyler Jacks, Independent Director
Brian McNamee, Executive Vice President - Full Potential Initiatives
Gregory Garland, Independent Director
Charles Holley, Director
Esteban Santos, Executive Vice President Operations
Jonathan Graham, Senior Vice President General Counsel, Secretary
Sean Harper, Executive Vice President - Research and Development
Mike Zahigian, VP Officer
Ellen Kullman, Director
Frank Biondi, Independent Director
Arvind Sood, IR Contact Officer
David Meline, CFO and Executive VP
Ronald Sugar, Independent Director
Stuart Tross, Senior Vice President - Human Resources
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Murdo Gordon, Executive Vice President of Global Commercial Operations
Peter Griffith, Ex CFO
Wanda Austin, Independent Director
Robert Eckert, Independent Director
Madhavan Balachandran, Executive VP of Operations
Lori Johnston, Senior Vice President - Human Resources
Brian Druker, Independent Director
Cynthia Patton, Senior Vice President Chief Compliance Officer
Greg Garland, Independent Director
Robert Williams, Independent Director
Judith Pelham, Independent Director
David Baltimore, Independent Director
Fred Hassan, Director
David Piacquad, Senior Vice President - Business Development
Anthony Hooper, Executive VP of Global Commercial Operations
David MD, Ex RD

Amgen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.66ROGN Roche Holding AGPairCorr

Moving against Amgen Stock

  0.65AXTELCPO Axtel SAB de Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Amgen Stock analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.